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Background: The Italian Renal Cell Cancer Early Access Program was an expanded
access program that allowed access to nivolumab, for patients (pts) with mRCC prior
to regulatory approval.
Methods: Pts with mRCC previously treated with agents targeting the vascular endo-
thelial growth factor pathway were eligible to receive nivolumab 3 mg/kg once every 2
weeks. Pts included in the analysis had received 1 dose of nivolumab and were moni-
tored for adverse events (AEs) using CTCAE v.4.0. Association between sex, age, BMI,
metastatic sites, number and kind of previous therapies, ECOG PS and related toxicity
were evaluated with a logistic regression model that identified only age 65 years
(Odds Ratio¼ 1.54 (1.00-2.38; P¼ 0.05).
Results: A total of 389 pts were enrolled between July 2015 and April 2016, 79% after 2
or more lines of therapy. The most common any-grade treatment-related AEs were
fatigue (13%) and rash (9%). Twenty-two (5.7%) pts discontinued treatment due to
AEs. There were no treatment-related deaths. Treatment-related AEs (grade 1-4) were
reported in 32% of pts. Median time to appearance of AEs was 1.4 months (range 0-
11.4). Grade 3–4 AEs occurred in 27 (7%) pts. Of the 22 serious AEs who induced treat-
ment discontinuation, 11 (50%) were considered irAEs including: grade 4 hyperglice-
mia (n¼ 1), grade 3 diarrhea (n¼ 1), grade 3 pulmonitis (n¼ 1), grade 3 bronchiolitis
obliterans organising pneumonia (BOOP) (n¼ 1), grade 3 asthenia (n¼ 1), grade 3
hypertension (n¼ 1), grade 3 skin toxicity (n¼ 1), grade 3 tremor (n¼ 1), grade 2 eye-
lid ptosis (n¼ 1), grade 2 liver toxicity (n¼ 1), grade 2 hypothyroidism (n¼ 1). AEs
were generally manageable with treatment as per protocol-specific guidelines. At a
median follow-up of 12 months, the median progression-free survival was 4.5 months
(95% CI 3.7 - 6.2), the 12-months overall survival rate was 63%. Pts with toxicity (124
pts) had a significant (P¼ 0.01) longer survival (1 year OS 69%) in comparison to pts
who did not experience AEs (1 year OS 59%).
Conclusions: The appearance of AEs strongly correlates with survival benefit in a real-
life population of mRCC pts treated with Nivolumab.
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Background: It is well established that renal cell carcinoma (RCC) is an obesity-associ-
ated cancer. Adiponectin, a major adipocyte-secreted adipokine, plays anti-tumor
properties in many malignancies, but exerted paradoxical actions on RCC. Herein, we
investigated the effects of adiponectin on RCC progression and resistance to sunitinib,
and to exploit this molecular mechanism.
Methods: Tissues were collected from 126 patients with metastatic renal cell carcinoma
(mRCC) treated with tyrosine kinase inhibitor (TKI) therapy. Tumor Adiponectine
receptor 1 (AdipoR1) and Adiponectine receptor 2 (AdipoR2) were detected by immu-
nohistochemistry. Assays with RCC cell lines were used to examine the signal transduc-
tion pathways of adiponectin in RCC.
Results: AdipoR2 was generally lower expressed than AdipoR1 in mRCC tumor
(15.6% vs 89.1%, p< 0.001). AdipoR1 expression, but not AdipoR2, was a significant
independent predictor of favorable responding to TKI and good survival outcomes. In
cultured RCC cells adiponectin inhibited migration and invasion of RCC cells and sen-
sitized cells to killing by sunitinib. Mechanistic investigations of ligand–receptor inter-
actions revealed that AdipoR1 could hinder migration and invasion of RCC cells by
blocking GSK3b and b-Catenin pathway and increase cells sensitivity to sunitinib
through inhibiting AKT and NF-jB pathway. However, AdipoR2 was not associated
with the tumor-limiting properties of adiponectin.
Conclusions: These results show that AdipoR1 is a potential prognostic marker for
favorable outcomes of mRCC patients. Adiponectin-AdipoR1 axis could be a plausible
target to impede tumor progression and sensitize tumors to TKI therapy.
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Background: Majority of patients (pts) with ccRCC at first line (1L) treatment are clas-
sified in the IR subgroup according to International Metastatic Renal Cell Carcinoma
Database Consortium (IMDC) model. IR represents a heterogeneous class of pts while
frontline strategies will be chosen on prognostic selection. The aim of this study is to
better characterize IR pts.
Methods: Retrospective analysis was performed from IGReCC (Institut Gustave
Roussy Renal Cell Carcinoma) database. Overall survival (OS) was defined from start
of 1L therapy to death or last follow-up. A multivariable Cox model with backward
selection procedure (alpha level¼ 0.01) and a Classification and Regression Tree
(CART) analysis were performed to identify which prognostic factors of IMDC score
(time from diagnosis to treatment [DDT]< 1 year, Karnofsky Performance Status
[KPS]< 80%, Hemoglobin< lower limit of normal [LNL], neutrophils> upper nor-
mal level [UNL], platelet>UNL, calcium>UNL) were associated to OS in IR pts.
Results: From 2005 to 2016, 777 pts with ccRCC were treated with an anti-VEGF first
line therapy. Among 571 evaluable pts for IMDC score, 199 (35%) pts were classified as
good risk, 82 (14%) as poor risk and 290 (51%) as IR. Median OS for IR pts was 24
months (mo). Within the IR population, only platelet (PLT) count was significantly
associated to OS with a hazard ratio 1.88 (95%CI 1.27-2.88) p¼ 0.0017. Median OS for
pts with PLT>UNL was 18 months (mo) [95%CI 12-23] versus 29 mo [95%CI 21.4-
35.7] for pts with normal PLT count. Therefore, the selection of PLT count was con-
firmed on bootstrap samples and was also selected for the first split of the CART-tree
analysis.
Conclusions: Pts in the IR group have a heterogeneous prognosis. Elevated PLT count
seems identifies a subgroup of pts with poor outcome in the IMDC intermediate-risk
population with ccRCC.
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Background: As slow disease progression is observed in a subset of mccRCC patients,
watchful waiting can be considered, thereby postponing toxicity of systemic treatment.
To identify those patients, the IMPACT trial evaluated the role of anti-Carbonic
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Anhydrase IX antibody 89Zr-girentuximab and 18F-fluorodeoxyglucose (FDG) PET/
CT (PET). Here, we report preliminary analyses of a secondary endpoint: comparison
of baseline contrast-enhanced(ce)CT, 89Zr-girentuximab and FDG PET to detect
metastases.
Methods: mccRCC pts with good or intermediate prognosis (according to IMDC) and
eligible for watchful waiting were included. Patients underwent 3 scans, i.e. ceCT, 89Zr-
girentuximab and 18F-FDG PET. So far, baseline scans of 29 of the 40 pts to be accrued
were independently reviewed by 3 experienced readers. Lesions by ceCT were defined
positive according to RECIST1.1. For lesions with prominent uptake of 89Zr-girentuxi-
mab or 18F-FDG, maximum Standardized Uptake Values (SUVmax) were calculated.
Analyses were performed on a lesion level, taking clustering of data within patients and
lesions into account.
Results: In total 325 lesions were detected by at least one modality (mean 11(2-33) per
pt); ceCT detected 52% (95%CI:45;58), 18F-FDG PET 61% (95%CI:55;67) and 89Zr-
girentuximab PET 69% (95%CI:63;74). Differences in lesion detection varied across
organ sites(p< 0.001). Lesions were visualized by ceCT and 18F-FDG PET in all
pts,whereas 89Zr-girentuximab PET detected lesions in 27 of 29 pts. Compared to
ceCT, 89Zr-girentuximab PET visualized additional lesions in all organ sites. Location
was strongly related with 89Zr-girentuximab uptake; highest uptake in kidney and adre-
nal gland tumor (mean SUVmax 63.2 and 70.3, resp) and lowest uptake in lung and
lymph nodes (mean SUVmax 10.9 and 15.0, resp). After correction for location, no
relation was observed between 89Zr-girentuximab SUVmax and tumor size, as meas-
ured by ceCT, and 18F-FDG SUVmax.
Conclusions: 89Zr-girentuximab and 18F-FDG PET visualize additional lesions com-
pared to ceCT, however correlation was poor. The addition of 89Zr-girentuximab or
18F-FDG PET might aid in deciding to either delay or start systemic treatment.
Clinical trial identification: NCT02228954.
Legal entity responsible for the study: Radboud University Medical Center
(Radboudumc).
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Background: In an era of increasing treatment options for mRCC, optimal treatment
sequence after IO therapy has not been well established. This study compares the effect
of targeted therapy (TT) (VEGFR TKI [axitinib, sunitinib, cabozantinib, pazopanib,
bevacizumab, and sorafenib] vs mTORI [everolimus and temsirolimus]) after progres-
sion on IO therapy.
Methods: Data from 7 International mRCC Database Consortium (IMDC) centers
were used to examine time to treatment discontinuation (TTD: time from TT initiation
to discontinuation for any reason) and objective response rate (ORR: complete or par-
tial tumor response) among mRCC patients (pts) treated with TT after IO between
2010-2018. Kaplan Meier analysis and Cox proportional hazards model adjusting for
age, sex, IMDC risk score, and line of therapy were conducted. Overall survival will be
reported when data is more mature.
Results: Pts treated with VEGFR TKI (N¼ 156 [85%]) and mTORI (N¼ 28 [15%])
post IO had similar age and IMDC risk scores (mean age: 61 vs 63 years; IMDC favor-
able: 5% vs 8%; IMDC intermediate: 62% vs 48%). Most common TT post IO were axi-
tinib (35%), cabozantinib (18%), and sunitinib (15%). Unadjusted median TTD was
significantly longer for VEGFR TKI vs mTORI (5.3 vs 2.5 months, p¼ 0.002). VEGFR
TKI vs mTORI post IO was significantly associated with a longer TTD (adjusted hazard
ratio [aHR]: 0.44, p¼ 0.002). A trend toward better TTD with axitinib post IO vs other
TT was observed (aHR: 0.66, p¼ 0.08). ORR was numerically higher in VEGFR TKI vs
mTORI. Reported results are across all lines of therapy. The table has descriptive
statistics.
Table: 889P Descriptive statistics of clinical outcomes among
patients treated with targeted therapy (i.e., VEGFR TKI, mTORI)
subsequent to IO treatment











All 184 118 (64) 4.9 (4.0, 5.6) 20 (17)
By class
VEGFR TKI2
All lines 156 93 (60) 5.3 (4.3, 6.9) 19 (20)
2nd line 44 28 (64) 3.8 (3.2, 5.4) 7 (23)
3rd line 72 43 (60) 5.7 (4.3, 9.8) 10 (22)
 4th line 40 22 (55) 6.1 (4.2, 10.9) 2 (10)
mTORI3
All lines 28 25 (89) 2.5 (1.4, 3.4) 1 (5)
2nd line 0 - - -
3rd line 20 19 (95) 2.3 (1.0, 4.9) 1 (6)
 4th line 8 6 (75) 3.2 (1.3, 4.9) 0 (0)
IO: immuno-oncology; VEGFR TKI: vascular endothelial growth factor
receptor tyrosine kinase inhibitor; mTORI: mammalian target of rapamycin
inhibitor; CI: confidence interval; ORR: objective response rate; TTD: time
to treatment discontinuation Notes: [1] Objective response rate, defined
as the sum of partial responses and complete responses, was assessed
during the line of targeted therapy subsequent to IO treatment. The total
number of patients assessed was 116. [2] VEGFR TKI included axitinib,
sunitinib, cabozantinib, pazopanib, bevacizumab, and sorafenib. [3]
mTORI included everolimus and temsirolimus.
Conclusions: Subsequent to IO therapy, VEGFR TKI pts had significantly longer
adjusted TTD than mTORI pts. When larger sample sizes are available for TT, further
examination of sequences is warranted.
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